[go: up one dir, main page]

WO2016191641A3 - Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l'aide d'une polythérapie comprenant des antigènes de capside de papillomavirus - Google Patents

Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l'aide d'une polythérapie comprenant des antigènes de capside de papillomavirus Download PDF

Info

Publication number
WO2016191641A3
WO2016191641A3 PCT/US2016/034539 US2016034539W WO2016191641A3 WO 2016191641 A3 WO2016191641 A3 WO 2016191641A3 US 2016034539 W US2016034539 W US 2016034539W WO 2016191641 A3 WO2016191641 A3 WO 2016191641A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
combination therapy
specific immune
immune responses
papillomavirus capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/034539
Other languages
English (en)
Other versions
WO2016191641A2 (fr
Inventor
Richard Roden
Tzyy-Choou Wu
Chien-Fu Hung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of WO2016191641A2 publication Critical patent/WO2016191641A2/fr
Publication of WO2016191641A3 publication Critical patent/WO2016191641A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés consistant à co-administrer à un mammifère une quantité efficace d'une polythérapie comprenant au moins un vecteur d'ADN comprenant un antigène de capside de papillomavirus et au moins un vaccin d'ADN comprenant un peptide antigénique, afin d'améliorer ainsi une réponse immunitaire spécifique à un antigène.
PCT/US2016/034539 2015-05-28 2016-05-27 Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l'aide d'une polythérapie comprenant des antigènes de capside de papillomavirus Ceased WO2016191641A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562167709P 2015-05-28 2015-05-28
US62/167,709 2015-05-28
US201562171711P 2015-06-05 2015-06-05
US62/171,711 2015-06-05

Publications (2)

Publication Number Publication Date
WO2016191641A2 WO2016191641A2 (fr) 2016-12-01
WO2016191641A3 true WO2016191641A3 (fr) 2017-01-12

Family

ID=57393352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/034539 Ceased WO2016191641A2 (fr) 2015-05-28 2016-05-27 Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l'aide d'une polythérapie comprenant des antigènes de capside de papillomavirus

Country Status (1)

Country Link
WO (1) WO2016191641A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3582790A4 (fr) 2017-02-16 2020-11-25 ModernaTX, Inc. Compositions immunogènes très puissantes
WO2022198093A1 (fr) * 2021-03-18 2022-09-22 Calyxt, Inc. Production d'albumine à l'aide de matrices de cellules végétales
WO2022198094A1 (fr) * 2021-03-18 2022-09-22 Calyxt, Inc. Production d'albumine dans des parties de plante cannabaceae
WO2022198085A2 (fr) * 2021-03-18 2022-09-22 Calyxt, Inc. Matrices de cellules végétales et leurs procédés
EP4475855A1 (fr) * 2022-02-11 2024-12-18 Washington University Procédés d'évaluation de cancer
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
CN115919819A (zh) * 2022-11-24 2023-04-07 华中科技大学同济医学院附属同济医院 6-姜酚在抑制hpv16感染中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649167B2 (en) * 1998-02-20 2003-11-18 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
WO2011017162A2 (fr) * 2009-08-03 2011-02-10 The Johns Hopkins University Méthodes permettant un renforcement des réponses immunitaires spécifiques à un antigène

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649167B2 (en) * 1998-02-20 2003-11-18 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
WO2011017162A2 (fr) * 2009-08-03 2011-02-10 The Johns Hopkins University Méthodes permettant un renforcement des réponses immunitaires spécifiques à un antigène

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI 20 September 2001 (2001-09-20), Database accession no. CAC51368.1 *
DATABASE NCBI 23 October 2008 (2008-10-23), Database accession no. CAB46515.1 *
DATABASE NCBI 23 October 2008 (2008-10-23), Database accession no. CAB57284.1 *

Also Published As

Publication number Publication date
WO2016191641A2 (fr) 2016-12-01

Similar Documents

Publication Publication Date Title
WO2016191641A3 (fr) Procédés pour améliorer des réponses immunitaires spécifiques à un antigène à l'aide d'une polythérapie comprenant des antigènes de capside de papillomavirus
WO2015142671A3 (fr) Vecteurs du virus de la grippe et leurs utilisations
PH12017500727A1 (en) Modified virus-like particles of cmv
EP4070818A3 (fr) Anticorps pd1 et pdl1 et combinaisons de vaccin et leur utilisation pour l'immunothérapie
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
WO2013106834A3 (fr) Peptides wt-1 immunogènes et leurs procédés d'utilisation
WO2014113490A3 (fr) Peptides wt-1 immunogènes et leurs procédés d'utilisation
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EP4378528A3 (fr) Vecteurs recombinants exprimant des antigènes du virus de la grippe aviaire et leurs utilisations
WO2017066706A8 (fr) Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse
EA201790239A1 (ru) Молекула-носитель для антигенов
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
WO2015195218A8 (fr) Particules pseudo-virales (ppv) grippales polyvalentes, et leur utilisation comme vaccins
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MY202196A (en) Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
BR112017004181A2 (pt) ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1?
EP3347045A4 (fr) Anticorps générés par le vaccin mva-gh/gl-pc neutralisant le pouvoir infectieux du cytomégalovirus humain et procédés associés
EP3452069A4 (fr) Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation
PL3504225T3 (pl) Nowe antygeny białkowe otoczki ludzkiego wirusa niedoboru odporności eksprymowane przez ssaki
DK3016673T3 (da) Pattedyrsmælkeosteopontin til forbedring af immunreaktion
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
WO2016090035A3 (fr) Modulateurs de l'activine et procédés de modulation de réponses immunitaires et de cellules t auxiliaires folliculaires
WO2017053525A3 (fr) Vaccin et thérapie contre la grippe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16800773

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16800773

Country of ref document: EP

Kind code of ref document: A2